Natasha Pardawala

Natasha has represented leading global companies and their directors and officers in federal and state jurisdictions. Her experience includes advising:

• Opiant Pharmaceuticals in its motion to dismiss post-close breach of fiduciary duty challenging disclosures and fairness of Indivior PLC’s acquisition of Opiant
• Directors of public companies in connection with shareholder demands and Delaware state court litigation involving claims for breach of fiduciary duties
• The Board of Directors of a breakthrough healthcare technology company in connection with a fast-paced proxy contest with an activist investment hedge fund
• A public biopharmaceutical company in connection with securities class action related to FDA approval of a rare disease drug
• An industry-disrupting oil & gas company in connection with an SEC investigation
• A leading health insurance company in multiple jurisdictions in connection with a breach of contract, violation of insurance codes, and unjust enrichment claims
• Directors and officers of a public company in connection with multiple lawsuits in multiple state and federal jurisdictions including securities class actions, derivative suits, and stockholder litigation alleging breach of fiduciary duties in connection with a merger
• Multiple public companies in connection with government investigations by the DOJ, SEC, and FTC, including achieving settlement of investigations
• Public companies in connection with disclosures related to large M&A transactions